Moderna

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Moderna and other ETFs, options, and stocks.

About MRNA

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.

CEO

Stéphane Bancel

CEOStéphane Bancel

Employees

5,600

Employees5,600

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

2010

Founded2010

Employees

5,600

Employees5,600

MRNA Key Statistics

Market cap

41.32B

Market cap41.32B

Price-Earnings ratio

-8.70

Price-Earnings ratio-8.70

Dividend yield

—

Dividend yield—

Average volume

2.50M

Average volume2.50M

High today

$108.48

High today$108.48

Low today

$105.39

Low today$105.39

Open price

$106.29

Open price$106.29

Volume

2.25M

Volume2.25M

52 Week high

$142.79

52 Week high$142.79

52 Week low

$62.55

52 Week low$62.55

MRNA News

Yahoo Finance 2d

Moderna Surpasses Market Returns: Some Facts Worth Knowing - Yahoo Finance

Moderna (MRNA) closed the most recent trading day at $107.97, moving +1.69% from the previous trading session. The stock outperformed the S&P 500, which registe...

Yahoo Finance 2d

Should You Buy Moderna Before May 12? - Yahoo Finance

Moderna (NASDAQ: MRNA) stock soared earlier in the pandemic as the company developed its coronavirus vaccine and the product went on to generate billions of dol...

Yahoo Finance 3d

Moderna To Present Respiratory & Cytomegalovirus Research at the ESCMID Global Congress - Yahoo Finance

CAMBRIDGE, MA / ACCESSWIRE / April 25, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present data from its respiratory portfolio, inc...

Analyst ratings

48%

of 25 ratings

Buy

48%

Hold

40%

Sell

12%

More MRNA News

Investor's Business Daily 4d

Analysts Expect Moderna's First-Quarter Sales To Plummet 95% — Is Moderna Stock A Sell?

Moderna (MRNA) stock is yo-yoing after the company unveiled early-stage test results for its Merck (MRK)-partnered cancer vaccine. X The companies tested a co...

Benzinga 4d

Moderna Stock Jumps On Collaboration With OpenAI: What's Going On?

Loading... Loading... Moderna Inc MRNA shares are trading higher Wednesday after the company announced an ongoing collaboration with OpenAI. What To Know: Mod...

Seeking Alpha 4d

Moderna and OpenAI in pact to fast-track drug development

Messenger RNA-based vaccine developer Moderna (NASDAQ:MRNA) has partnered with OpenAI to deploy San Francisco-based AI firm's ChatGPT Enterprise across its busi...

Benzinga 5d

Moderna Faces Pfizer, BioNTech in London Patent Battle over Covid-19 Vaccines In Legal Showdown

Loading... Loading... Moderna Inc. MRNA is set to clash with Pfizer Inc. PFE and BioNTech SE BNTX in a pivotal London patent trial concerning the development o...

Seeking Alpha 5d

Moderna Investors Should Beware Patent-Dispute Fallout - Seeking Alpha

carmengabriela Shares in Moderna (NASDAQ:MRNA), maker of the breakthrough mRNA shot against Covid-19, jumped to a three-month high this month [April 2024] afte...

Seeking Alpha 6d

Moderna stock closes in green after eight sessions of losses

Moderna (NASDAQ:MRNA) closed in green and snapped an eight-day losing streak after having lost 4% over the last eight trading sessions. Shares of the pharmaceu...

Simply Wall St 6d

Moderna, Inc.'s Prospects Need A Boost To Lift Shares - Simply Wall St

With a price-to-sales (or "P/S") ratio of 5.7x Moderna, Inc. ( ) may be sending very bullish signals at the moment, given that almost half of all the Biotechs c...